Depatuxizumab Mafodotin

**Semantic type:** Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) consisting of depatuxizumab, a humanized monoclonal antibody directed against human epidermal growth factor receptor (EGFR), conjugated to the auristatin derivative monomethyl auristatin F (MMAF), with potential antineoplastic activity. Upon administration of depatuxizumab mafodotin, depatuxizumab targets and binds to EGFR expressed on tumor cell surfaces. Upon internalization, the MMAF moiety is released, binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest, tumor cell apoptosis and inhibition of cellular proliferation in tumor cells that overexpress EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.

**Synonyms:** - ABT-414 - DEPATUXIZUMAB MAFODOTIN